The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

pentavere.com

Founded Year

2016

Stage

Incubator/Accelerator | Alive

About Pentavere Research Group

Pentavere is an early-stage digital health company working with 6 of the top-10 largest pharmaceutical in the world. The company is the developer of a proprietary artificial intelligence (AI) engine that is proven and validated to transform complex clinical documentation into usable real-world evidence and lifesaving insights. Pentavere’s big pharma customers have deployed its AI technology across their entire value chains to inform strategic decisions and enhance clinical workflows, improving operational efficiencies and saving significant costs. The company was founded in 2016 and is based in Toronto, Ontario.

Pentavere Research Group Headquarter Location

661 University Avenue Suite 1300, MaRS Centre, West Tower

Toronto, Ontario, M5G 0B7,

Canada

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Pentavere Research Group

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pentavere Research Group is included in 2 Expert Collections, including Value-Based Care & Population Health.

V

Value-Based Care & Population Health

866 items

The VBC & Population Health collection includes companies that enable and deliver care models that address the health needs for defining populations along the continuum of care, including in the community setting, through participation, engagement, and targeted interventions.

D

Digital Health

12,808 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Latest Pentavere Research Group News

08:01 EDT Takeda Canada Innovation Challenge Awarded to Pentavere to Accelerate Rare Disease Diagnosis and Care Using New AI Tec...

May 11, 2022

FOR CANADIAN AUDIENCES ONLY Toronto-based Pentavere will collaborate with Takeda Canada and receive dedicated funding for new proof-of-concept AI project focused on Rare Disease care Innovation Challenge was launched to find new partners and identify breakthrough ideas to support advancements in Rare Disease diagnoses through AI technology Investment will support Rare Disease Real-World Evidence (RWE) analysis across Canada TORONTO, May 11, 2022 /CNW/ - Takeda Canada Inc. is pleased to announce Pentavere Research Group Inc. has been awarded the first Takeda Canada Innovation Challenge. The Innovation Challenge was launched in January 2022 to accelerate partnerships in identifying new digital technologies and artificial intelligence (AI) solutions that support enhanced patient care in inflammatory bowel disease (IBD) or rare disease conditions. Pentavere Research Group Inc. is a clinical discovery company that has developed a breakthrough, proprietary, artificial intelligence (AI) engine called DARWEN™, which accelerates discovery from vast amounts of clinical text. DARWEN™ unlocks value, insights and evidence from clinical information which is impossible to analyze by human intelligence alone. "We are thrilled to have the opportunity to collaborate with Pentavere to leverage their AI technology within the field of rare diseases," said Rute Fernandes, General Manager, Takeda Canada. "Building strong partnerships across our healthcare ecosystem and leveraging data and technology is imperative to holistically address key patient needs, from diagnostics right through to personalized medicine. We would like to congratulate Pentavere on its successful submission and to thank all entrants for participating in the Takeda Canada Innovation Challenge." Pentavere will have the opportunity to collaborate and benefit from Takeda's expertise and extensive international network, as well as funding, to build a proof of concept project in the areas of rare diseases. "Our team is incredibly excited to learn that Pentavere and our AI engine, DARWEN™, have been selected as the winning submission in the Takeda Canada Innovation Challenge," said Aaron Leibtag, Co-Founder and CEO, Pentavere Research Group. "We are delighted to be collaborating with Takeda Canada and to be working with its team of experts to unlock the knowledge buried in millions of pages of clinical information. Together we will be generating the data, insights and breakthrough solutions we need to improve the lives of patients living with rare diseases. We would like to thank Takeda Canada for this opportunity and its ongoing commitment to investing in Canadian innovation that can scale globally."    The Takeda Canada Innovation Challenge received multiple submissions within the fields of early diagnosis or integrated and personalized care, applicable to the therapeutic areas of inflammatory bowel disease (ulcerative colitis or Crohn's disease) or rare genetic diseases. "We could not be more pleased with the number of quality submissions that this important initiative received," said Dr. Jefferson Tea, Vice President, Medical and Scientific Affairs, Takeda Canada. "Takeda firmly believes that partnering with others is essential to identify and continuously explore new options to support patients at every step through their journey. About Takeda Canada Inc. Takeda Canada Inc. is the Canadian organization of Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK), a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discovering and delivering life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit: takeda.com/en-ca SOURCE Takeda Canada Inc.

  • When was Pentavere Research Group founded?

    Pentavere Research Group was founded in 2016.

  • Where is Pentavere Research Group's headquarters?

    Pentavere Research Group's headquarters is located at 661 University Avenue, Toronto.

  • What is Pentavere Research Group's latest funding round?

    Pentavere Research Group's latest funding round is Incubator/Accelerator.

  • Who are the investors of Pentavere Research Group?

    Investors of Pentavere Research Group include JLabs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.